NASDAQ · BOLD

Boundless Bio, Inc.

Healthcare · Biotechnology

$2.66▲ 2.31% ($0.06)at close

After hours$2.64▼ 0.83%5:04 PM ET

52-week

$0.96$3.16

Market cap

$59.78M

P/E

-0.93

EPS (TTM)

-$2.85

Next earnings

Nov 5, 2026

Valuation

Earnings yield

No estimate

Earnings yield isn't available here

A positive earnings figure and a usable price are needed to calculate earnings yield.

USD · Financial statements through Jun 30, 2026 · EPS source period not supplied · Price used $2.66 · Price Sep 25, 8:00 PM UTC

Your edits update the card above as you go.

Earnings yield · Maximum entry price

Unavailable

Projected annual return:: Unavailable
Current earnings yield:: Unavailable
10-year Treasury benchmark:: 5.18%

Entry price is a return-based threshold, not an estimate of value.

A positive earnings figure and a usable price are needed to calculate earnings yield.

USD · Financial statements through 2026-06-30 · EPS source period not supplied

Estimate an entry price from future earnings and your required return. Growth and the exit P/E change the forecast; current earnings yield uses only EPS and the price used.

Earnings per sharePer share · USD

Annual EPS growth percent

Target price-to-earnings multiple

Holding period in years

Required annual return percent

Add a positive EPS and exit P/E, and an EPS growth assumption to calculate the forecast.

EPS basis: reported EPS unavailable in the price currency. Current earnings yield: —. Dividends are excluded from projected annual return.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 135.4%FCF (TTM): -0.87%

What changed

The stock rose 135.4% over the last year. Free cash flow declined 0.87% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher with no clear directional signal from operating metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.

Return analysis

Company profile

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors.

CEOZachary Hornby

SectorHealthcare

IndustryBiotechnology

Employees28

IPO dateMar 28, 2024

https://boundlessbio.com

Market multiples

Forward P/E—

EV/EBITDA-1.02

Enterprise value$58M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-67.86%▼21.2ppvs FY2025

Analyst consensus

RatingHold

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.56 · Revenue est —

View

Institutional Sentiment

Boundless Bio, Inc. · BOLD

From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.

NASDAQ · BOLD

Boundless Bio, Inc.

Healthcare · Biotechnology

$2.66▲ 2.31% ($0.06)at close

After hours$2.64▼ 0.83%5:04 PM ET

52-week

$0.96$3.16

Market cap

$59.78M

P/E

-0.93

EPS (TTM)

-$2.85

Next earnings

Nov 5, 2026

Valuation

Earnings yield

No estimate

Earnings yield isn't available here

A positive earnings figure and a usable price are needed to calculate earnings yield.

USD · Financial statements through Jun 30, 2026 · EPS source period not supplied · Price used $2.66 · Price Sep 25, 8:00 PM UTC

Your edits update the card above as you go.

Earnings yield · Maximum entry price

Unavailable

Projected annual return:: Unavailable
Current earnings yield:: Unavailable
10-year Treasury benchmark:: 5.18%

Entry price is a return-based threshold, not an estimate of value.

A positive earnings figure and a usable price are needed to calculate earnings yield.

USD · Financial statements through 2026-06-30 · EPS source period not supplied

Estimate an entry price from future earnings and your required return. Growth and the exit P/E change the forecast; current earnings yield uses only EPS and the price used.

Earnings per sharePer share · USD

Annual EPS growth percent

Target price-to-earnings multiple

Holding period in years

Required annual return percent

Add a positive EPS and exit P/E, and an EPS growth assumption to calculate the forecast.

EPS basis: reported EPS unavailable in the price currency. Current earnings yield: —. Dividends are excluded from projected annual return.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 135.4%FCF (TTM): -0.87%

What changed

The stock rose 135.4% over the last year. Free cash flow declined 0.87% over the trailing twelve months.

What the market seems to be pricing

What would invalidate this read

A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.

Return analysis

Company profile

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors.

CEOZachary Hornby

SectorHealthcare

IndustryBiotechnology

Employees28

IPO dateMar 28, 2024

https://boundlessbio.com

Market multiples

Forward P/E—

EV/EBITDA-1.02

Enterprise value$58M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-67.86%▼21.2ppvs FY2025

Analyst consensus

RatingHold

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.56 · Revenue est —

View

Institutional Sentiment

Boundless Bio, Inc. · BOLD

From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.